DDX53 and neoplasm: The prodrug activation efficacy of this system was confirmed in vitro with various cancer cell lines, including HeLa, CMS5a, and CT26, and in vivo with a CT26‐bearing mouse model, in which tumor inhibition was confirmed by a significant reduction in tumor volume.